|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2006-5-9
|
|
pubmed:abstractText |
The use of doxorubicin (DOX) as a chemotherapeutic agent is limited by cardiac injury. Iloprost, a stable synthetic analogue of prostacyclin, has previously been shown to protect against DOX-induced cardiomyocyte injury in vitro. Here, we addressed whether iloprost is cardioprotective in vivo and whether it compromises the anti-tumour efficacy of DOX.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0195-668X
|
|
pubmed:author |
pubmed-author:AustinSandra CSC,
pubmed-author:DeflandreCatherineC,
pubmed-author:FitzgeraldDesmond JDJ,
pubmed-author:HalpernElkan FEF,
pubmed-author:HarmeyJudy HJH,
pubmed-author:JassalDavinder SDS,
pubmed-author:KayElaineE,
pubmed-author:McAllisterHesterH,
pubmed-author:NeilanTomas GTG,
pubmed-author:RamA BAB,
pubmed-author:ScullyMichael FMF
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1251-6
|
|
pubmed:meshHeading |
pubmed-meshheading:16624831-Animals,
pubmed-meshheading:16624831-Antibiotics, Antineoplastic,
pubmed-meshheading:16624831-Apoptosis,
pubmed-meshheading:16624831-Carcinoma, Lewis Lung,
pubmed-meshheading:16624831-Cardiomyopathies,
pubmed-meshheading:16624831-Cell Division,
pubmed-meshheading:16624831-Doxorubicin,
pubmed-meshheading:16624831-Drug Interactions,
pubmed-meshheading:16624831-Iloprost,
pubmed-meshheading:16624831-Lung Neoplasms,
pubmed-meshheading:16624831-Male,
pubmed-meshheading:16624831-Mice,
pubmed-meshheading:16624831-Mice, Inbred C57BL,
pubmed-meshheading:16624831-Myocytes, Cardiac,
pubmed-meshheading:16624831-Neoplasm Transplantation,
pubmed-meshheading:16624831-Tumor Cells, Cultured
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression.
|
|
pubmed:affiliation |
Department of Clinical Pharmacology, Institute of Biopharmaceutical Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland. tneilan@partners.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
